Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to ...

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.